Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc experienced a remarkable 41.6% year-over-year growth in total revenue for the fourth quarter, surpassing estimates by 1.5%, indicating strong demand and effective operational performance. The partnership with Helios is anticipated to enhance margins significantly by 2026 and 2027, with expectations for margins to expand back to the 12%-15% range as contracts mature. Furthermore, the company is poised for sustainable positive earnings growth, supported by the addition of $30 million to $35 million in capitated revenue from year-to-date deals, positioning the company favorably within the expanding oncology market.

Bears say

The Oncology Institute Inc. is facing significant financial challenges, as evidenced by a substantial year-over-year decline of 71.4% in revenue from its Clinical Trials & Other segment, which generated only $0.7 million. The company reported an adjusted EBITDA of $0.1 million, representing a marginal 0.1% margin, which fell well short of expectations due to lower gross margins and ongoing contract losses impacting profitability. Additionally, with dispensary margins affected by changes in fees leading to a $15 million headwind, the company’s growth trends in oncology appear to be flat or in low single digits, raising concerns about its ability to achieve projected break-even EBITDA by late 2025.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.